Design and implementation of cell-based assays to model human disease

ACS Chemical Biology

Volumn 2, Issue 11, 2007, Pages 718-724

  Jones, Jeremy O ^a   Diamond, Marc I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BETA LACTAM ANTIBIOTIC; BICALUTAMIDE; CELL NUCLEUS RECEPTOR; COMPLEMENTARY DNA; DYSTROPHIN; ESTROGEN RECEPTOR; TAMOXIFEN;

ACCURACY; AMYOTROPHIC LATERAL SCLEROSIS; CELL ASSAY; CONFORMATIONAL TRANSITION; CYTOLOGY; DEGENERATIVE DISEASE; DEVELOPMENTAL BIOLOGY; DISEASE MODEL; DRUG ACTIVITY; DRUG TARGETING; GENE EXPRESSION; GENETIC SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN GENOME; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR MECHANICS; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REVIEW; RNA INTERFERENCE; SAFETY;

CELLS; DRUG EVALUATION, PRECLINICAL; GENE LIBRARY; HUMANS; MODELS, BIOLOGICAL; SMALL MOLECULE LIBRARIES;

EID: 37349031430     PISSN: 15548929     EISSN: None     Source Type: Journal    
DOI: 10.1021/cb700177u     Document Type: Review

References (38)

1. La Rosee, P., O'Dwyer, M. E., and Druker, B. J. (2002) Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective, Leukemia 16, 1213-1219.
2. Bandyopadhyay, S., Ni, J., Ruggiero, A., Walshe, K., Rogers, M. S., Chattopadhyay, N., Glicksman, M. A., and Rogers, J. T. (2006) A high-throughput drug screen targeted to the 5′-untranslated region of Alzheimer amyloid precursor protein mRNA, J. Biomol. Screening 11, 469-480.
3. Ahn, J. S., Musacchio, A., Mapelli, M., Ni, J., Scinto, L, Stein, R., Kosik, K. S., and Yeh, L. A. (2004) Development of an assay to screen for inhibitors of tau phosphorylation by cdk5, J. Biomol. Screening 9, 122-131.
4. Kosik, K. S., Ahn, J., Stein, R., and Yeh, L. A. (2002) Discovery of compounds that will prevent tau pathology, J. Mol. Neurosci. 19, 261-266.
5. Yager, D., Watson, M., Healy, B., Eckman, E. A., and Eckman, C. B. (2002) Natural product extracts that reduce accumulation of the Alzheimer's amyloid beta peptide: selective reduction in A beta42, J. Mol. Neurosci. 19, 129-133.
6. Haugabook, S. J., Le, T., Yager, D., Zenk, B., Healy, B. M., Eckman, E. A., Prada, C., Younkin, L., Murphy, P., Pinnix, I., Onstead, L., Sambamurti, K., Golde, T. E., Dickson, D., Younkin, S. G., and Eckman, C. B. (2001) Reduction of Abeta accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin, FASEB J. 15, 16-18.
7. Utsuki, T., Yu, Q. S., Davidson, D., Chen, D., Holloway, H. W., Brossi, A., Sambamurti, K., Lahiri, D. K., Greig, N. H., and Giordano, T. (2006) Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide, J. Pharmacol. Exp. Ther. 318, 855-862.
8. Morse, L. J., Payton, S. M., Cuny, G. D., and Rogers, J. T. (2004) FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein, J. Mol. Neurosci. 24, 129-136.
9. Coufal, M., Maxwell, M. M., Russel, D. E., Amore, A. M., Altmann, S. M., Hollingsworth, Z. R., Young, A. B., Housman, D. E., and Kazantsev, A. G. (2007) Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments, J. Biomol. Screening 12, 351-360.
10. Hu, M., Schurdak, M. E., Puttfarcken, P. S., El Kouhen, R., Gopalakrishnan, M., and Li, J. (2007) High content screen microscopy analysis of Abeta(1-42)-induced neurite outgrowth reduction in rat primary cortical neurons: neuroprotective effects of alpha7 neuronal nicotinic acetylcholine receptor ligands, Brain Res. 1151, 227-35.
11. Wang, W., Duan, W., Igarashi, S., Morita, H., Nakamura, M., and Ross, C. A. (2005) Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model, Neurobiol. Dis. 20, 500-508.
12. Zhang, X., Smith, D. L., Meriin, A. B., Engemann, S., Russel, D. E., Roark, M., WA, S. L, Maxwell, M. M., Marsh, J. L., Thompson, L. M., Wanker, E. E., Young, A. B., Housman, D. E., Bates, G. P., Sherman, M. Y., and Kazantsev, A. G. (2005) A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo, Proc. Natl. Acad. Sci. U.S.A. 102, 892-897.
13. Stack, E. C., Kubilus, J. K., Smith, K., Cormier, K., Del Signore, S. J., Guelin, E., Ryu, H., Hersch, S. M., and Ferrante, R. J. (2005) Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice, J. Comp. Neurol. 490, 354-370.
14. Li, J. Y., Popovic, N., and Brundin, P. (2005) The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies, NeuroRx 2, 447-464.
15. Gregory, C. A., Serra-Mestres, J., and Hodges, J. R. (1999) Early diagnosis of the Frontal variant of frontotemporal dementia: how sensitive are standard neuroimaging and neuropsychologic tests? Neuropsychiatry Neuropsychol. Behav. Neurol. 12, 128-135.
16. Zoghbi, H. Y., and Orr, H. T. (2000) Glutamine repeats and neurogeneration, Annu. Rev. Neurosci. 23, 217-247.
17. Pollitt, S. K., Pallos, J., Shao, J., Desai, U. A., Ma, A. A., Thompson, L. M., Marsh, J. L., and Diamond, M. I. (2003) A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor, Neuron 40, 685-694.
18. Finkelstein, R., Miller, T., and Baughman, R. (2002) The challenge of translational research - a perspective from the NINDS, Nat. Neurosci. 5 Suppl., 1029-1030.
19. Abbott, A. (2002) Neurologists strike gold in drug screen effort, Nature 417, 109.
20. Desai, U. A., Pallos, J., Ma, A. A., Stockwell, B. R., Thompson, L. M., Marsh, J. L, and Diamond, M. I. (2006) Biologically active molecules that reduce polyglutamine aggregation and toxicity, Hum. Mol. Genet. 15, 2114-2124.
21. Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., Toan, S. V., Bruijn, L. I., Su, Z. Z., Gupta, P., and Fisher, P. B. (2005) Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression, Nature 433, 73-77.
22. Welch, E. M., Barton, E. R., Zhuo, J., Tomizawa, Y., Friesen, W. J., Trifillis, P., Paushkin, S., Patel, M., Trotta, C. R., Hwang, S., Wilde, R. G., Karp, 6., Takasugi, J., Chen, G., Jones, S., Ren, H., Moon, Y. C., Corson, D., Turpoff, A. A., Campbell, J. A., Conn, M. M., Khan, A., Almstead, N. G., Hedrick, J., Mollin, A., Risher, N., Weetall, M., Yeh, S., Branstrom, A. A., Colacino, J. M., Babiak, J., Ju, W. D., Hirawat, S., Northcutt, V. J., Miller, L. L., Spatrick, P., He, F., Kawana, M., Feng, H., Jacobson, A., Peltz, S. W., and Sweeney, H. L. (2007) PTC124 targets genetic disorders caused by nonsense mutations, Nature 447, 87-91.
23. Culig, Z., Klocker, H., Bartsch, G., Steiner, H., and Hobisch, A. (2003) Androgen receptors in prostate cancer, J. Urol. 170, 1363-1369.
24. Shao, W., and Brown, M. (2004) Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy, Breast Cancer Res. 6, 39-52.
25. Komer, W., Vinggaard, A. M., Terouanne, B., Ma, R., Wieloch, C., Schlumpf, M., Sultan, C., and Soto, A. M. (2004) Interlaboratory comparison of four in vitro assays for assessing androgenic and antiandrogenic activity of environmental chemicals, Environ. Health Perspect. 112, 695-702.
26. Schaufele, F., Carbonell, X., Guerbadot, M., Bomgraeber, S., Chapman, M. S., Ma, A. A., Miner, J. N., and Diamond, M. I. (2005) The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions, Proc. Natl. Acad. Sci. U.S.A. 102, 9802-9807.
27. Cvoro, A., Paruthiyil, S., Jones, J. O., Tzagarakis-Foster, C., Clegg, N. J., Tatomer, D., Medina, R. T., Tagliaferri, M., Schaufele, F., Scanlan, T. S., Diamond, M. I., Cohen, I., and Leitman, D. C. (2007) Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract, Endocrinology 148, 538-547.
28. Kim, S. B., Ozawa, T., Watanabe, S., and Umezawa, Y. (2004) High-throughput sensing and noninvasive imaging of protein nuclear transport by using reconstitution of spilt Renilla luciferase, Proc. Natl. Acad. Sci. U.S.A. 101, 11542-11547.
29. Savkur, R. S., and Burris, T. P. (2004) The coactivator LXXLL nuclear receptor recognition motif, J. Pept. Res. 63, 207-212.
30. Zhou, G., Cummings, R., Li, Y., Mitra, S., Wilkinson, H. A., Elbrecht, A., Hermes, J. D., Schaeffer, J. M., Smith, R. G., and Moller, D. E. (1998) Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer, Mol. Endocrinol. 12, 1594-1604.
31. Awais, M., Sato, M., Sasaki, K., and Umezawa, Y. (2004) A genetically encoded fluorescent indicator capable of discriminating estrogen agonists from antagonists in living cells, Anal Chem. 76, 2181-2186.
32. Irwin, J. J. (2006) How good is your screening library? Curr. Opin. Chem. Biol. 10, 352-356.
33. Golebiowski, A., Klopfenstein, S. R., and Portlock, D. E. (2003) Lead compounds discovered from libraries: part 2, Curr. Opin. Chem. Biol. 7, 308-325.
34. Golebiowski, A., Klopfenstein, S. R., and Portlock, D. E. (2001) Lead compounds discovered from libraries, Curr. Opin. Chem. Biol. 5, 273-284.
35. Diamond, M. I., Robinson, M. R., and Yamamoto, K. R. (2000) Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor, Proc. Natl. Acad. Sci. U.S.A. 97, 657-661.
36. Clardy, J., and Walsh, C. (2004) Lessons from natural molecules, Nature 432, 829-837.
37. Butler, M. S. (2005) Natural products to drugs: natural product derived compounds in clinical trials, Nat. Prod. Rep. 22, 162-195.
38. Irwin, J. J., and Shoichet, B. K. (2005) ZINC - a free database of commercially available compounds for virtual screening, J. Chem. Inf. Model. 45, 177-182.